-
Health Commission: 22 newly diagnosed cases on the 10th, including 9 from the local area
Time of Update: 2021-06-16
As of 24:00 on June 10, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are currently 426 confirmed cases (including 12 severe cases), 86,297 cured and discharged cases, and 4,636 deaths.
-
Nuocheng Jianhua's FGFR inhibitor gunagratinib was approved as an orphan drug by the U.S. FDA
Time of Update: 2021-06-16
Nuocheng Jianhua announced today that the company's self-developed highly selective pan-FGFR (fibroblast growth factor receptor) inhibitor gunagratinib (ICP-192) has been granted Orphan Drug designation by the U.
Among the 12 FGF/FGFR gene mutation-positive patients who completed at least one tumor evaluation, the objective response rate (ORR) was 33.
-
A new round of provincial-level centralized procurement is about to start in Anhui, bidding and bargaining determine the selected enterprises
Time of Update: 2021-06-11
Designated medical institutions that give priority to the use of selected drugs and fulfill their contracts as required shall be encouraged in accordance with the relevant policies for the retention of the balance of the medical insurance fund for centralized procurement of drugs.
-
The United States, with a surplus of vaccines, finally announced the first batch of 25 million doses of vaccine global distribution plan
Time of Update: 2021-06-11
US President Biden promised in May that he would share 80 million doses of the new crown vaccine with the world by the end of June, but he has not announced a detailed distribution plan before.
-
Qianjin Pharmaceutical: Antiplatelet drug ticagrelor tablets approved for marketing
Time of Update: 2021-06-11
On June 2, Qianjin Pharmaceutical issued an announcement stating that its holding subsidiary had received the "Drug Registration Certificate" for ticagrelor tablets approved by the State Food and Drug Administration.
Ticagrelor tablet is an antiplatelet drug developed by AstraZeneca Pharmaceutical Co.
-
Poinsettia: Omeprazole Sodium for Injection passed the consistency evaluation
Time of Update: 2021-06-11
Mainly used for: ① bleeding from peptic ulcer, bleeding from anastomotic ulcer; ② acute gastric mucosal damage in an emergency state, acute gastric mucosal damage caused by non-steroidal anti-inflammatory drugs; ③ prevention of severe diseases (such as cerebral hemorrhage, severe Trauma, etc.
1 in sales of peptic ulcer injection products.
-
Poinsettia subsidiary obtains the registration certificate of Levocetirizine Hydrochloride Oral Drops
Time of Update: 2021-06-11
On May 26, Poinsettia issued an announcement stating that its wholly-owned subsidiary Guangzhou Poinsettia Pharmaceutical Co.
recently received the "Drug Registration Certificate" approved and issued by the State Drug Administration.
Levocetirizine hydrochloride, as a third-generation antihistamine, has antihistamine and anti-inflammatory dual anti-allergic effects.
-
Hengrui Medicine: Paricalcitol injection passed the consistency evaluation of generic drugs
Time of Update: 2021-06-11
On May 25, Hengrui Medicine stated that it had recently received the "Drug Supplementary Application Approval Notice" for Paricalcitol injection approved and issued by the National Medical Products Administration.
Up to now, the total R&D cost of Paricalcitol injection generic drug consistency evaluation project is about 4.
-
Xintian Pharmaceutical's avanafil tablets obtained drug registration approval
Time of Update: 2021-06-11
Recently, Xintian Pharmaceutical issued an announcement stating that its wholly-owned subsidiary Huilun Jiangsu Pharmaceutical received the approval of the National Medical Products Administration to issue a "drug registration certificate" for avanafil tablets.
Avanafil is a generic drug product developed by Huilun Jiangsu Pharmaceutical.
-
A pharmacy fined 2 million yuan, the strictest supervision is coming
Time of Update: 2021-06-11
5 million for the sale of counterfeit drugs and starting with a fine of 100,000 for the sale of inferior drugsIt can be seen from the above cases that the current penalties for illegally selling inferior drugs in pharmacies are strictly implemented in accordance with the new drug management law, and the penalties are much greater than the previous regulations.
-
2 billion anti-tumor drugs!
Time of Update: 2021-06-11
On June 3, the official website of the State Administration of Food and Drug Administration showed that Qilu Pharmaceutical (Hainan) imatinib mesylate tablets were approved for production of imatinib mesylate tablets in 4 categories, which were deemed to have been reviewed and became the fourth domestic manufacturer.
-
All these restrictions on opening pharmacies have been lifted
Time of Update: 2021-06-11
Open a pharmacy, only use one certificateOpen a pharmacy, only use one certificateAs early as March last year, the Shandong Provincial Marketing Bureau made it clear at its work meeting that this year it would explore the pilot reform of "one industry, one license", and guide the municipal administrative examination and approval departments to collect licensing matters and issue a comprehensive license.
-
Lunvatinib: Chia Tai Tianqing uses his spear to attack his shield and is expected to win market exclusivity for one year
Time of Update: 2021-06-11
Picture source: State Intellectual Property OfficeThe requester for the invalidation of the two patents was Nanjing Chia Tai Tianqing Pharmaceutical Co.
Picture source: State Intellectual Property OfficeThis time, CP Tianqing requested the 2010 lenvatinib preparation patent that the core evidence is CN101001629.
-
Sumitomo Pharma's Class 1 new drug for schizophrenia was approved for clinical use
Time of Update: 2021-06-11
Article source: Pharmaceutical GuanlanAccording to the latest announcement by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration, Sumitomo Dainippon Pharma's Class 1 new drug SEP-363856 tablets have obtained four clinical trials with implied approval, and it is planned to develop the treatment of schizophrenia.
-
Jiudian Pharmaceutical: Ornidazole tablets passed the consistency evaluation of generic drugs
Time of Update: 2021-06-11
On May 31, Hunan Jiudian Pharmaceutical stated that ornidazole tablets passed the consistency evaluation of the quality and efficacy of generic drugs.
As of the date of this announcement, Jiudian Pharmaceutical is one of the three domestic companies that have passed the consistency evaluation of ornidazole tablets.
-
How to develop better CDK inhibitors behind the US$5 billion?
Time of Update: 2021-06-11
(PS: Nearly 1/3 of the global CDK inhibitor clinical trials are carried out on CDK4/6, see the figure below for details)Image source: Bioorganic & Medicinal Chemistry LettersReference: doi.
-
An increase of nearly 200% in five years!
Time of Update: 2021-06-11
Continued rapid growth According to Meinenet data, in 2020, the total amount of drugs used in public hospitals in key provinces and cities in China has exceeded 200 billion yuan, and the digestion, metabolism and anti-diabetic drug market accounted for 14.
-
13 exclusive Chinese patent medicines for cardiovascular and cerebrovascular diseases, eye-catching step length, Tasly...
Time of Update: 2021-06-11
2020 China's public medical institutions' terminal cardiovascular and cerebrovascular Chinese patent medicines TOP10 brands Source: Mi Nei. com, China's public medical institutions terminal competition pattern Three new brands are on the TOP20 list, namely Yindan Xinnaotong Soft Capsule of Guizhou Bailing Enterprise Group (%2011.
-
Zhu Ning returns to GSK China!
Time of Update: 2021-06-11
At 5 o'clock yesterday, GSK China announced that Zhu Ning will serve as vice president, head of market access and commercial operations, effective from June 15th, and a member of the leadership team of GSK China's prescription drugs and vaccines department, based in Shanghai.
-
No need to change pregnancy risk data label GlaxoSmithKline wins Zofran safety lawsuit
Time of Update: 2021-06-11
Therefore, Judge Saylor believes that the FDA refused to add pregnancy warning labels in accordance with the obligations imposed on it by federal law, and the US federal law takes precedence over the plaintiff’s claim in state law that no safety warning has been issued.
